001435745 000__ 05838cam\a2200553\i\4500
001435745 001__ 1435745
001435745 003__ OCoLC
001435745 005__ 20230309003951.0
001435745 006__ m\\\\\o\\d\\\\\\\\
001435745 007__ cr\un\nnnunnun
001435745 008__ 210413s2021\\\\si\\\\\\o\\\\\000\0\eng\d
001435745 019__ $$a1284940017
001435745 020__ $$a9789813360440$$q(electronic bk.)
001435745 020__ $$a9813360445$$q(electronic bk.)
001435745 020__ $$z9789813360433
001435745 020__ $$z9813360437
001435745 0247_ $$a10.1007/978-981-33-6044-0$$2doi
001435745 035__ $$aSP(OCoLC)1245927201
001435745 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dGW5XE$$dOCLCO$$dEBLCP$$dCASUM$$dOCLCO$$dOCLCF$$dUX1$$dUKAHL$$dOCLCQ$$dOCLCO$$dCOM$$dOCLCQ
001435745 049__ $$aISEA
001435745 050_4 $$aRC537
001435745 08204 $$a616.85/27$$223
001435745 24500 $$aMajor depressive disorder :$$brethinking and understanding recent discoveries /$$cYong-Ku Kim, editor.
001435745 264_1 $$aSingapore :$$bSpringer,$$c[2021]
001435745 300__ $$a1 online resource
001435745 336__ $$atext$$btxt$$2rdacontent
001435745 337__ $$acomputer$$bc$$2rdamedia
001435745 338__ $$aonline resource$$bcr$$2rdacarrier
001435745 4901_ $$aAdvances in experimental medicine and biology,$$x0065-2598 ;$$vvolume 1305
001435745 5050_ $$aSection I. Re-thinking depression from a network perspective -- Chapter 1. Phenotype network and brain structural covariance network of major depression -- Chapter 2. Task MRI-based functional brain network of major depression -- Chapter 3. White matter-based structural brain network of major depression -- Chapter 4. The application of a machine learning-based brain MRI approach in major depression -- Chapter 5. Resting state functional MRI in major depression -- Chapter 6. Development of neuroimaging-based biomarkers in depressive disorder -- Section II. Current diagnostic and neurobiological issues -- Chapter 7. Challenges and strategies for current classifications of depressive disorders: proposal for future diagnostic standards -- Chapter 8. Epigenetics: a missing link between early life stress and depression -- Chapter 9. Glia- neuron communications and gut-brain axis in depression -- Chapter 10. Apoptosis and proliferation markers in major depression -- Chapter 11. A load to find clinically useful biomarkers for depression -- Chapter 12. Pharmacogenomic tests for diagnosis and treatment prediction in depression -- Section III. Current specific treatments for depression -- Chapter 13. Biofeedback and neurofeedback for depression: a critical review -- Chapter 14. Cognitive behavioral therapy and mindfulness based cognitive therapy for depressive disorders -- Chapter 15. Acceptance Commitment Therapy (ACT) for major depressive disorder -- Chapter 16. Neurostimulation therapies in depressive disorders -- Chapter 17. Ketamine in major depression : New rapid antidepressant -- Chapter 18. Psychodynamic therapy in depressive disorders -- Chapter 19. Well-being therapy in depressive disorders -- Chapter 20. Complementary and alternative medicine in the treatments of depressive disorders -- Chapter 21. Current psychopharmacology algorithm for major depressive disorder -- Section IV. Promising future treatments for depression -- Chapter 22. Novel psychopharmacology for depressive disorders -- Chapter 23. Cannabinoid agents for depressive disorders -- Chapter 24. Virtual Reality for the treatment of depressive disorders -- Chapter 25. Epigenetic Therapy in depressive disorders -- Chapter 26. Induced pluripotent stem (iPS) cells technology: potential therapeutic targets for depression -- Chapter 27. Vaccination and immunotherapy for major depression -- Chapter 28. Psychedelic Medicines in major depression: progress and future challenges -- Chapter 29. Precision Psychiatry: Biomarker guided Tailored Therapy for Effective Treatment and Prevention in major depression.
001435745 506__ $$aAccess limited to authorized users.
001435745 520__ $$aThis book reviews all aspects of major depressive disorder (MDD), casting light on its neurobiological underpinnings and describing the most recent advances in management. The book is divided into four sections, the first of which discusses MDD from a network science perspective, highlighting the alterations in functional and structural connectivity and presenting insights achieved through resting state functional MRI and the development of neuroimaging-based biomarkers. The second section examines important diagnostic and neurobiological issues, while the third considers the currently available specific treatments for MDD, including biofeedback, neurofeedback, cognitive behavioral therapy, acceptance and commitment therapy, neuromodulation therapy, psychodynamic therapy, and complementary and alternative medicine. A concluding section is devoted to promising emerging treatments, from novel psychopharmacological therapies through to virtual reality treatment, immunotherapy, biomarker-guided tailored therapy, and more. Written by leading experts from across the world, the book will be an excellent source of information for both researchers and practitioners.
001435745 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed April 14, 2021).
001435745 650_0 $$aDepression, Mental.
001435745 650_0 $$aDepression, Mental$$xPathogenesis.
001435745 650_0 $$aDepression, Mental$$xTreatment.
001435745 650_6 $$aDépression.
001435745 650_6 $$aDépression$$xPathogenèse.
001435745 650_6 $$aDépression$$xTraitement.
001435745 655_0 $$aElectronic books.
001435745 7001_ $$aKim, Yong-Ku,$$eeditor.
001435745 77608 $$iPrint version:$$tMajor depressive disorder.$$dSingapore : Springer, [2021]$$z9813360437$$z9789813360433$$w(OCoLC)1222897406
001435745 830_0 $$aAdvances in experimental medicine and biology ;$$vv. 1305.$$x0065-2598
001435745 852__ $$bebk
001435745 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-981-33-6044-0$$zOnline Access$$91397441.1
001435745 909CO $$ooai:library.usi.edu:1435745$$pGLOBAL_SET
001435745 980__ $$aBIB
001435745 980__ $$aEBOOK
001435745 982__ $$aEbook
001435745 983__ $$aOnline
001435745 994__ $$a92$$bISE